Xeris Biopharma Holdings, Inc.
xerispharma.comWhat Do They Do?
Sells Recorlev, Gvoke and Keveyis, prescription treatments for people with endocrine and neurological diseases, and develops injectable medicines and formulation technologies for pharmaceutical partners.
10-K for FY2025, filed Mar 2, 2026We are a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine…View ↗
Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for…View ↗
XP-8121: We are in the process of developing the first and only, once-weekly, subcutaneous injection of levothyroxine for the treatment of…View ↗
How Do They Make Money?
Most revenue comes from selling medicines to wholesalers and a specialty pharmacy, with product sales counted when those buyers receive the goods. Royalty and collaboration revenue is earned under contract terms.
10-K for FY2025, filed Mar 2, 2026The Company sells product primarily to wholesalers or a specialty pharmacy that subsequently resell to retail pharmacies or patients. The…View ↗
Revenue is recognized when the Company's customer (e.g., a wholesaler or specialty pharmacy) obtains control of promised goods, which is…View ↗
Royalty and contract revenue is recognized as earned in accordance with contract terms when it can be reasonably estimated and…View ↗
-
10-K for FY2025, filed Mar 2, 2026
FY2025 revenue by product or service ↗
$291.8M
-
10-K for FY2025, filed Mar 2, 2026
$291.8M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue, net
Sold outright
10-K for FY2025, filed Mar 2, 2026 |
97%
FY2022: 99%
|
Product revenue, net, FY2025
$283M Sources
|
Sold outright |
|
Royalty, contract and other revenue
Licensed
|
3.0%
FY2022: 0.9%
|
Royalty, contract and other revenue, FY2025
$8.8M Sources
|
Licensed |
Who Are Their Customers?
Xeris sells its products to wholesalers and a specialty pharmacy, which then resell them to retail pharmacies or patients.
10-K for FY2025, filed Mar 2, 2026The Company sells product primarily to wholesalers or a specialty pharmacy that subsequently resell to retail pharmacies or patients. The…View ↗
Do Revenues Turn Into Profits?
Yes. It kept less than a cent of every revenue dollar as net income in FY2025.
10-K for FY2025, filed Mar 2, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$31.1MView ↗
- ▲ +1513% (Loss)
- vs −$1.9M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 6, 2026
Open tableView ↗
-
Aug 6, 2026
Tightened full-year revenue guidance to $385 million to $390 million
Sources
8-K, filed Aug 6, 2026
Tightens full-year 2026 total revenue guidance to $385 million to $390 millionView ↗
-
Jun 30, 2026
CEO John Shannon was appointed board chair
Marla S. Persky was designated lead independent director.
Sources
8-K, filed Jun 30, 2026
On June 29, 2026, the Board appointed John Shannon, the Company’s Chief Executive Officer, to serve as Chairperson of the Board, effective…View ↗
Growing. Revenue grew 5.9x in 4 years, from $49.6M in FY2021 to $291.8M in FY2025, about 56% a year.
Who Do They Compete With?
Competes with Corcept Therapeutics, Teva Pharmaceutical Industries, Recordati, HRA Pharma, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, Stero Therapeutics, Lundbeck, Amphastar, Zealand Pharma, Fresenius Kabi, Torrent Pharmaceuticals, Cycle Pharmaceuticals, and Rising Pharmaceuticals
10-K for FY2025, filed Mar 2, 2026Recorlev: A number of therapies are currently approved or in various stages of development for endogenous Cushing’s syndrome. Korlym…View ↗
Loading...
